Literature DB >> 3734105

Use of alpha 2 adrenoreceptor agonists and antagonists in the functional assessment of the sympathetic nervous system.

D Robertson, M R Goldberg, C S Tung, A S Hollister, R M Robertson.   

Abstract

We studied the effects of clonidine, an alpha 2-adrenoreceptor agonist, and yohimbine, an alpha 2-adrenoreceptor antagonist, on blood pressure, heart rate, and plasma catecholamines in 12 patients with autonomic dysfunction. Clonidine (0.1 mg, orally) lowered blood pressure 18 +/- 3 torr in six subjects and raised it 5 +/- 1 torr in six. The change in blood pressure in response to this dose of clonidine was inversely proportional to the supine level of norepinephrine (P less than 0.05). Yohimbine (4-64 micrograms/kg) raised plasma norepinephrine and blood pressure in six patients with degenerative autonomic dysfunction. Yohimbine also attenuated by 50% (P less than 0.05) the hypotensive response to head-up tilt of patients with degenerative autonomic dysfunction. Clonidine depends upon postjunctional hypersensitivity and the degree of autonomic insufficiency to elicit its pressor response. In contrast, the pressor response to yohimbine is related to the capacity of the sympathetic nervous system to be activated and release norepinephrine. If plasma norepinephrine levels following yohimbine administration are monitored, the biochemical and hemodynamic response to the drug may provide a sensitive indication of the capacity of the sympathetic nervous system to be activated in patients with autonomic dysfunction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3734105      PMCID: PMC423596          DOI: 10.1172/JCI112611

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  Increased vascular beta2-adrenoceptor responsiveness in autonomic dysfunction.

Authors:  D Robertson; A S Hollister; E L Carey; C S Tung; M R Goldberg; R M Robertson
Journal:  J Am Coll Cardiol       Date:  1984-03       Impact factor: 24.094

2.  Hypersensitivity of adrenergic receptors and blood-pressure response to oral yohimbine in orthostatic hypotension.

Authors:  O E Brodde; M Anlauf; J Arroyo; R Wagner; F Weber; K D Buck
Journal:  N Engl J Med       Date:  1983-04-28       Impact factor: 91.245

3.  An acute psychotic episode at the beginning of clonidine therapy.

Authors:  A Elizur; Z Liberson
Journal:  Prog Neuropsychopharmacol       Date:  1980

4.  Hemodynamic and humoral effects of caffeine in autonomic failure. Therapeutic implications for postprandial hypotension.

Authors:  J Onrot; M R Goldberg; I Biaggioni; A S Hollister; D Kingaid; D Robertson
Journal:  N Engl J Med       Date:  1985-08-29       Impact factor: 91.245

5.  Acute hallucinosis due to clonidine.

Authors:  M D Enoch; G E Hammad
Journal:  Curr Med Res Opin       Date:  1977       Impact factor: 2.580

6.  Pharmacologic distinction of different orthostatic hypotension syndromes.

Authors:  R J Polinsky; I J Kopin; M H Ebert; V Weise
Journal:  Neurology       Date:  1981-01       Impact factor: 9.910

7.  Clonidine raises blood pressure in severe idiopathic orthostatic hypotension.

Authors:  D Robertson; M R Goldberg; A S Hollister; D Wade; R M Robertson
Journal:  Am J Med       Date:  1983-02       Impact factor: 4.965

8.  The sympathetic-nervous-system defect in primary orthostatic hypotension.

Authors:  M G Ziegler; C R Lake; I J Kopin
Journal:  N Engl J Med       Date:  1977-02-10       Impact factor: 91.245

Review 9.  Orthostatic hypotension.

Authors:  J E Thomas; A Schirger; R D Fealey; S G Sheps
Journal:  Mayo Clin Proc       Date:  1981-02       Impact factor: 7.616

10.  Influence of yohimbine on blood pressure, autonomic reflexes, and plasma catecholamines in humans.

Authors:  M R Goldberg; A S Hollister; D Robertson
Journal:  Hypertension       Date:  1983 Sep-Oct       Impact factor: 10.190

View more
  14 in total

1.  Autonomic dysfunction: diagnosis guided by therapy.

Authors:  R M Robertson; I Biaggioni; R Mosqueda-Garcia; D Robertson
Journal:  Trans Am Clin Climatol Assoc       Date:  1992

Review 2.  Neurocardiology: therapeutic implications for cardiovascular disease.

Authors:  David S Goldstein
Journal:  Cardiovasc Ther       Date:  2010-11-25       Impact factor: 3.023

3.  Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure.

Authors:  Luis E Okamoto; Cyndya Shibao; Alfredo Gamboa; Leena Choi; André Diedrich; Satish R Raj; Bonnie K Black; David Robertson; Italo Biaggioni
Journal:  Hypertension       Date:  2012-02-06       Impact factor: 10.190

Review 4.  Management of Supine Hypertension Complicating Neurogenic Orthostatic Hypotension.

Authors:  Jacquie Baker; Kurt Kimpinski
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

5.  Catecholamines 101.

Authors:  David S Goldstein
Journal:  Clin Auton Res       Date:  2010-07-11       Impact factor: 4.435

6.  Autoimmune autonomic failure in a patient with myeloma-associated Shy-Drager syndrome.

Authors:  D S Goldstein; A McRae; C Holmes; M C Dalakas
Journal:  Clin Auton Res       Date:  1996-02       Impact factor: 4.435

Review 7.  Effect of water drinking on sympathetic nervous activity and blood pressure.

Authors:  Jens Jordan
Journal:  Curr Hypertens Rep       Date:  2005-02       Impact factor: 5.369

8.  The head and neck discomfort of autonomic failure: an unrecognized aetiology of headache.

Authors:  D Robertson; D W Kincaid; V Haile; R M Robertson
Journal:  Clin Auton Res       Date:  1994-06       Impact factor: 4.435

9.  Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans.

Authors:  C N Andrews; A E Bharucha; M Camilleri; P A Low; B M Seide; D D Burton; K K Nickander; K L Baxter; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2007-09       Impact factor: 3.598

Review 10.  Current pharmacologic treatment for orthostatic hypotension.

Authors:  Roy Freeman
Journal:  Clin Auton Res       Date:  2008-03-27       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.